NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

This strategy has already resulted in the Sanofi partnership we announced this year, which has enabled us to transition away ...

Novavax Inc (NVAX) reports increased product sales and a strong cash position, while revising revenue guidance and navigating ...

In its recent third-quarter 2024 earnings report, Novavax highlighted significant advancements in its vaccine portfolio, including the removal of a clinical hold by the U.S. FDA on its ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Health agencies, counties and state officials have been resisting efforts to provide booster jabs to Americans this fall.

Dynavax Technologies Corporation's flagship product, Heplisav-B, continues to increase market share consistently in a growing ...

A third dose of COVID-19 vaccine offered essential workers some protection from developing long COVID during Omicron variant ...